^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    19h
    Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov)
    P2, N=90, Recruiting, AIM ImmunoTech Inc. | Trial completion date: Apr 2028 --> Jul 2028
    Trial completion date
    |
    Ampligen (rintatolimod)
    2d
    KEYNOTE-E02: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=692, Recruiting, Seagen Inc. | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tivdak (tisotumab vedotin-tftv)
    3d
    TRIPP-FFX: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=80, Recruiting, OncoSil Medical Limited | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    3d
    Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver (clinicaltrials.gov)
    P1, N=1, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Dec 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • BAP1 (BRCA1 Associated Protein 1) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • FANCC (FA Complementation Group C)
    |
    BRCA1 mutation • PALB2 mutation
    |
    MSK-IMPACT
    |
    cisplatin • gemcitabine
    3d
    Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Recruiting, Yale University | Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    oxaliplatin • irinotecan
    5d
    Study on Cadonilimab Plus mFOLFIRINOX in patients with locally advanced pancreatic cancer (ChiCTR2400088986)
    P=N/A, N=30, Not yet recruiting, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New trial • Metastases
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    oxaliplatin • irinotecan • Kaitanni (cadonilimab)
    7d
    NEO-IMPACT: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer (ACTRN12622000378729)
    P2, N=20, Active, not recruiting, Australasian Gastro-Intestinal Trials Group (AGITG) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    5-fluorouracil • oxaliplatin • irinotecan
    7d
    Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 13
    Enrollment closed • Enrollment change • Surgery
    |
    Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • oleclumab (MEDI9447)
    9d
    Causal associations of tea consumption on risk of pancreatic adenocarcinoma and the mediating role of vascular endothelial growth factor D levels. (PubMed, Br J Nutr)
    The two-step MR analysis of results showed that only VEGF-D played a mediating role, with a mediation ratio of 0·230 (0·066, 0·394). In conclusion, the findings suggest that VEGF-D mediates the effect of tea intake on the risk of pancreatic adenocarcinoma.
    Journal
    |
    VEGFD (Vascular Endothelial Growth Factor D)
    9d
    Tyme-88-Panct: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2/3, N=130, Terminated, Tyme, Inc | Completed --> Terminated; Sponsor's decision
    Trial termination • Metastases
    |
    gemcitabine • 5-fluorouracil • capecitabine • sirolimus • racemetyrosine (SM-88)
    10d
    Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer With Homologous Recombination Deficiency That Has Spread to the Liver (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • BAP1 (BRCA1 Associated Protein 1) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • FANCC (FA Complementation Group C)
    |
    BRCA1 mutation • PALB2 mutation
    |
    MSK-IMPACT
    |
    cisplatin • gemcitabine
    10d
    Pancancer analysis of the interactions between CTNNB1 and infiltrating immune cell populations. (PubMed, Medicine (Baltimore))
    Additionally, pathway enrichment suggested that NUMB is involved in the Wnt pathway. This study highlights the predictive role of CTNNB1 across cancers, suggesting that CTNNB1 might serve as a potential biomarker for the diagnosis and prognosis evaluation of various malignant tumors.
    Journal • Pan tumor • Immune cell
    |
    CD8 (cluster of differentiation 8) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • RHOA (Ras homolog family member A)
    |
    CTNNB1 mutation • CTNNB1 expression
    14d
    FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | N=10 --> 24
    Enrollment change
    15d
    Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) (clinicaltrials.gov)
    P3, N=571, Completed, NovoCure Ltd. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    gemcitabine • albumin-bound paclitaxel
    15d
    Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas. (PubMed, EMBO Mol Med)
    In summary, vaccination against the endogenous fibroblast target ADAM12 effectively depletes CAFs, reduces desmoplasia and delays the growth of murine PDACs. These results provide proof-of-principle for the development of vaccination-based immunotherapies to treat tumor desmoplasia.
    Preclinical • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ADAM12 (ADAM Metallopeptidase Domain 12)
    18d
    Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=12, Active, not recruiting, Fox Chase Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    18d
    Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma. (PubMed, ESMO Open)
    No abstract available
    Journal • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    19d
    Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort. (PubMed, J Natl Cancer Inst)
    Adjuvant mFFX is effective and tolerable in resected PDAC in a non-trial setting, including for patients >70 years.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • HRD (Homologous Recombination Deficiency)
    |
    KRAS mutation • HRD
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    19d
    Comprehensive bioinformatics analysis of the prognostic value and immune infiltration of CAPN2 in pancreatic adenocarcinoma. (PubMed, Gene)
    CAPN2 is a promising biomarker for PAAD prognosis and a potential therapeutic target. Its association with the TME and immunotherapy response highlights its importance in PAAD progression and patient outcomes, warranting further investigation into its role and potential clinical applications.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CAPN2 (Calpain 2)
    21d
    Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. (PubMed, Ther Adv Med Oncol)
    Studies on the clinical significance and treatment response to 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) regimen in terms of the presence of these mutations remain inconclusive. PDAC patients with wild-type TP53 demonstrated longer OS than those with TP53 mutation, and this trend was intensified in patients with localized disease. This result may be due to an impaired response to FOLFIRINOX chemotherapy in patients with TP53 mutation.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • KRAS mutation • TP53 wild-type
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    22d
    Proton-PANC: Study of Proton Therapy in Adjuvant Pancreatic Cancer (clinicaltrials.gov)
    P1, N=9, Completed, Georgetown University | Recruiting --> Completed | Trial completion date: Dec 2021 --> Nov 2023
    Trial completion • Trial completion date
    |
    oxaliplatin • irinotecan • dexamethasone injection • fosaprepitant • ondansetron intravenous
    23d
    Circ_0005397/miR-326 and linc00152/miR-216b share the signaling pathway of PDK2 to promote pancreatic adenocarcinoma oncogenesis. (PubMed, Arch Med Sci)
    No abstract available
    Journal
    |
    MIR326 (MicroRNA 326) • CYTOR (Cytoskeleton Regulator RNA)
    24d
    Niraparib in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation
    |
    Zejula (niraparib)
    24d
    Construction and validation of senescence risk score signature as a novel biomarker in liver hepatocellular carcinoma: a bioinformatic analysis. (PubMed, Transl Cancer Res)
    In summary, comprehensive analyses supported that the SRSS model can better predict survival and risk in LIHC patients. Promisingly, it may point out a brand-new direction for LIHC therapy.
    Journal
    |
    IGFBP3 (Insulin-like growth factor binding protein 3) • SOCS2 (Suppressor Of Cytokine Signaling 2) • RACGAP1 (Rac GTPase activating protein 1)
    25d
    CAR T Cell Immunotherapy for Pancreatic Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Pennsylvania | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    26d
    HKDC1 promotes autophagy and proliferation in pancreatic adenocarcinoma through interaction with PARP1 and poly(ADP-ribosyl)ation. (PubMed, Cell Signal)
    HKDC1 plays a critical role in the malignant progression of PAAD by activating autophagy and promoting cell proliferation. Our findings suggest that targeting HKDC1 and its downstream signaling pathways may provide novel strategies for PAAD treatment.
    Journal • PARP Biomarker
    |
    CCND1 (Cyclin D1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • PCNA (Proliferating cell nuclear antigen)
    |
    CCND1 expression • PCNA expression
    28d
    TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Nov 2024
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    28d
    Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A)
    |
    HRD
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    29d
    QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=138, Completed, NantCell, Inc. | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    gemcitabine • ganitumab (AMG 479) • conatumumab (AMG 655)
    29d
    "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways. (PubMed, J Evid Based Integr Med)
    HLJDD inhibited PAAD in vitro and in vivo via the modulation of multiple mechanisms, including regulation of PI3K/AKT/mTOR and MAPK/ERK1/2 signaling pathways.
    Journal
    |
    IL17A (Interleukin 17A)
    29d
    Expression of Trefoil Factor 1 (TFF1) in Cancer: A Tissue Microarray Study Involving 18,878 Tumors. (PubMed, Diagnostics (Basel))
    The link between TFF1 expression and parameters of malignancy argues for a relevant biological role of TFF1 in cancer. TFF1 may represent a suitable therapeutic target due to its expression in only a few normal cell types.
    Journal
    |
    PGR (Progesterone receptor) • TFF1 (Trefoil Factor 1)
    |
    PGR expression
    29d
    Combined PET Radiotracer Approach Reveals Insights into Stromal Cell-Induced Metabolic Changes in Pancreatic Cancer In Vitro and In Vivo. (PubMed, Cancers (Basel))
    In contrast, FAPα expression increased in both PanC-1 and multi-cellular xenograft models over time due to invasion of mouse fibroblasts. Conclusion The presented models are suitable for subsequently characterizing stromal cell-induced metabolic changes in tumors using noninvasive molecular imaging techniques.
    Preclinical • Journal • Stroma
    |
    FAP (Fibroblast activation protein, alpha)
    29d
    A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC (clinicaltrials.gov)
    P=N/A, N=258, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed
    Trial completion
    |
    AKR1B10 (Aldo-Keto Reductase Family 1 Member B10) • CA 19-9 (Cancer antigen 19-9)
    1m
    Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, HonorHealth Research Institute | Trial completion date: Sep 2024 --> Dec 2024
    Trial completion date • Metastases
    |
    cisplatin • gemcitabine • paclitaxel • hydroxychloroquine
    1m
    Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=263, Active, not recruiting, Salubris Biotherapeutics Inc | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • SAL008
    1m
    Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Jul 2025 --> Apr 2028 | Trial primary completion date: Dec 2024 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    CD38 (CD38 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1m
    SPORE: A Study of Pembrolizumab and Olaparib for People with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • BAP1 (BRCA1 Associated Protein 1) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • FANCC (FA Complementation Group C)
    |
    MSK-IMPACT
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    1m
    SPECC1 as a pan-cancer biomarker: unraveling its role in drug sensitivity and resistance mechanisms. (PubMed, Discov Oncol)
    Drug sensitivity assay showed that SPECC1 high-expressing cell lines were more sensitive to docetaxel, doxorubicin, etc. In conclusion, the current study shows how SPECC1 is expressed in different cancers and how this expression relates to the prognosis of the tumor. This study looks at the response of SPEC1 expression to anticancer therapy. Explains the prognostic significance and drug response of SPECC-1.
    Journal • BRCA Biomarker • Pan tumor
    |
    BRCA (Breast cancer early onset) • SPECC1 (Sperm Antigen With Calponin Homology And Coiled-Coil Domains 1)
    |
    docetaxel • doxorubicin hydrochloride
    1m
    PANCREAS: Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery (clinicaltrials.gov)
    P2, N=30, Recruiting, Hamilton Health Sciences Corporation | Trial primary completion date: May 2024 --> Dec 2025
    Trial primary completion date
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    1m
    PESTIPAC: Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=56, Completed, CHU de Reims | Recruiting --> Completed
    Trial completion
    1m
    Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study. (PubMed, EBioMedicine)
    The combination of genomic and transcriptomic analyses of primary pancreatic tumours enables us to distinguish metastatic tumours from other tumour types. Our molecular strategy may assist in predicting overall survival outcomes for platinum or gemcitabine-based chemotherapies, as well as radio-chemotherapy.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • HRD (Homologous Recombination Deficiency) • RNF43 (Ring Finger Protein 43)
    |
    TP53 mutation • KRAS mutation • HRD • TP53 wild-type • RNF43 mutation
    |
    gemcitabine
    1m
    Extracellular vesicles from cancer cell lines of different origins drive the phenotype of normal oral fibroblasts in a CAF-like direction. (PubMed, Front Oncol)
    The fibroblast response was dependent on EV origin and concentration, and duration of EV exposure. The present results indicate that the molecular cargo of the EVs direct NOFs towards a pro-tumorigenic phenotype.
    Preclinical • Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle) • ANO1 (Anoctamin 1)